Predictive factors for cytomegalovirus infection after orthotopic liver transplantation using an ultrasensitive polymerase chain reaction assay

Transplant Proc. 2006 Sep;38(7):2339-41. doi: 10.1016/j.transproceed.2006.06.114.

Abstract

The predictive factors for cytomegalovirus (CMV) infection in de novo liver transplant patients were determined at 3 months posttransplantation. We included all consecutive patients except those who died or who had lost their graft within 1 month posttransplant. We recorded both donor (D) and recipient (R) data. Immunosuppression utilized tacrolimus, steroids, with or without mycophenolate mofetil, and/or induction therapy with anti-CD25 monoclonal antibodies. CMV prophylaxis was administered only to those at high risk of CMV infection, namely, D+/R- patients. These cases received intravenous ganciclovir at 500 mg/d for the first 2 weeks followed by oral ganciclovir at 500 mg for the following 3 months. The median time to CMV infection was 1 month. The significant predictive factors for CMV infection were D/R CMV status, (P = .002): D+/R+ versus other patients (P = .01), D-/R- versus other patients (P = .002), D+ versus D- (P = .009). In addition infection was associated with the original liver disease (hepatitis C virus infection or alcohol-related cirrhosis; P = .03), R+ vs. R- (P = .03), donor age (<45 or >45 years; P = .01), lymphocyte count at M2 (< or >1300/mm(3); P = .02), hemoglobin levels at 1 and 3 months, and platelet and white blood cell counts at day 7. The independent predictive factors were recipient CMV sero-status (R+ vs R-; odds ratio = 10.2), donor age >45 years (odds ratio = 11.4) and lymphocyte count at M2 <1300/mm(3) (odds ratio = 7.33). This study showed that the major factors associated with CMV infection were recipient CMV status, donor age, and lymphocyte count.

MeSH terms

  • Base Sequence
  • Cytomegalovirus / genetics*
  • Cytomegalovirus / isolation & purification
  • Cytomegalovirus Infections / epidemiology*
  • Cytomegalovirus Infections / prevention & control*
  • DNA Primers
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Liver Transplantation / adverse effects*
  • Liver Transplantation / immunology
  • Lymphocyte Count
  • Middle Aged
  • Polymerase Chain Reaction
  • Postoperative Complications / virology*
  • Predictive Value of Tests
  • Tissue Donors

Substances

  • DNA Primers
  • Immunosuppressive Agents